Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H17ClN2O4.ClH |
Molecular Weight | 409.263 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OCC(O)COC(=O)C1=C(NC2=C3C=CC(Cl)=CC3=NC=C2)C=CC=C1
InChI
InChIKey=CEUMONXVSJOJIH-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O4.ClH/c20-12-5-6-14-17(7-8-21-18(14)9-12)22-16-4-2-1-3-15(16)19(25)26-11-13(24)10-23;/h1-9,13,23-24H,10-11H2,(H,21,22);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H17ClN2O4 |
Molecular Weight | 372.802 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/1675606Curator's Comment: description was created based on several sources, including
http://www.thepharmaletter.com/article/glafenine-french-temp-withdrawal
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1675606
Curator's Comment: description was created based on several sources, including
http://www.thepharmaletter.com/article/glafenine-french-temp-withdrawal
Glafenine is a non-steroidal anti-inflammatory drug (NSAID). Glafenine was withdrawn due to the risk of anaphylaxis and acute kidney failure.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5421810 |
Primary | Unknown Approved UseUnknown |
||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4141989 |
Secondary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl)alkyl 2-aminobenzoates and 2-aminonicotinates. | 1979 May |
|
[Detection and diagnosis of drug induced lithiasis]. | 1983 |
|
[Occurrence of drug reactions]. | 1986 |
|
Analgesic and non-steroidal anti-inflammatory drug-associated acute renal failure: a prospective collaborative study. | 1986 Jun |
|
[Identification of a metabolite of floctafenine in urinary calculi]. | 1987 |
|
[13 cases of drug-induced calculi]. | 1988 |
|
Immunogenicity of amodiaquine in the rat. | 1990 |
|
Recurrence of biliary drug lithiasis due to dipyridamole. | 1997 Jun |
|
Synthesis and pharmacological evaluation of analgesic 6-substituted 2(3H)-benzothiazolones. | 2001 |
|
Impact of glafenine hydrochloride on human endothelial cells and human vascular smooth muscle cells: a substance reducing proliferation, migration and extracellular matrix synthesis. | 2003 |
|
Cytokine release does not improve the sensitivity and specificity of the direct popliteal lymph node assay. | 2004 Aug 5 |
|
High-performance liquid chromatographic determination of proquazone and its m-hydroxy metabolite in spiked human plasma and urine. | 2007 Jul-Aug |
|
Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay. | 2009 Jul 15 |
|
A novel flow cytometric high throughput assay for a systematic study on molecular mechanisms underlying T cell receptor-mediated integrin activation. | 2009 Jun 25 |
|
Correction of the Delta phe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. | 2010 Jun |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ndrugs.com/?s=glafenine%20hydrochloride
200-400 mg, 3-4 times per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14642530
human aortic smooth muscle cells (haSMCs) and human endothelial cells (ECs) were seeded in tissue culture flasks. The cells were treated for 4 days with glafenine hydrochloride (10 uM, 50 uM, 100 uM). Half of the treated groups were incubated again with glafenine hydrochloride, the other half received medium free of glafenine hydrochloride every 4 days until day 20.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:04:12 GMT 2023
by
admin
on
Sat Dec 16 10:04:12 GMT 2023
|
Record UNII |
MS23T96ZZP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
MS23T96ZZP
Created by
admin on Sat Dec 16 10:04:12 GMT 2023 , Edited by admin on Sat Dec 16 10:04:12 GMT 2023
|
PRIMARY | |||
|
100000086288
Created by
admin on Sat Dec 16 10:04:12 GMT 2023 , Edited by admin on Sat Dec 16 10:04:12 GMT 2023
|
PRIMARY | |||
|
65513-72-6
Created by
admin on Sat Dec 16 10:04:12 GMT 2023 , Edited by admin on Sat Dec 16 10:04:12 GMT 2023
|
PRIMARY | |||
|
3085326
Created by
admin on Sat Dec 16 10:04:12 GMT 2023 , Edited by admin on Sat Dec 16 10:04:12 GMT 2023
|
PRIMARY | |||
|
SUB02339MIG
Created by
admin on Sat Dec 16 10:04:12 GMT 2023 , Edited by admin on Sat Dec 16 10:04:12 GMT 2023
|
PRIMARY | |||
|
DTXSID7045497
Created by
admin on Sat Dec 16 10:04:12 GMT 2023 , Edited by admin on Sat Dec 16 10:04:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |